Navigation Links
Different drug combinations work best for prevention versus treatment of colorectal tumors
Date:4/7/2013

WASHINGTON, DC (April 7, 2013)Colorectal cancer is the second leading cause of cancer-related deaths in the United States. Once colorectal cancer has spread to other parts of the body, only 11 percent of patients will survive five years from the date of their diagnosis. Most colorectal cancers are adenocarcinomascancers that begin in cells that make and release mucus and other fluids. Adenocarcinomas begin as benign tumors called adenomas, which become malignant over time. By treating adenomas before they become cancerous, it could be possible to prevent colorectal cancer.

Researchers at Fox Chase Cancer Center have tested the effectiveness of two promising drugs in preventing and treating colorectal adenomas in mice. A team led by Wen-Chi Chang, PhD, assistant research professor at Fox Chase, found that the effect of these drugs, which have already been approved by the Food and Drug Administration for the treatment of other conditions, depends on whether adenomas are present when drug treatment begins. Chang will present these findings at the AACR Annual Meeting 2013 on Sunday, April 7.

"We often get focused on either the preventive or therapeutic setting and don't think about how these drugs are maybe serving more than one purpose," says senior author on the study Margie L. Clapper, PhD, co-leader of the Cancer Prevention and Control Program at Fox Chase. "The most exciting thing for us was to be able to track these tumors and for the first time distinguish between prevention and chemotherapy, and to show that one agent is maybe effective in both settings if used appropriately, or in this case, in combination with another agent."

Past studies in animals have shown that colorectal tumors can be suppressed by combined treatment with two drugs: a non-steroidal anti-inflammatory compound called sulindac and a cholesterol-lowering medication called atorvastatinwhose brand name is Lipitor. But in those studies, tumors were induced in an unnatural waythrough exposure to carcinogenic chemicalswhereas in humans, cancer often has genetic origins.

To evaluate the effectiveness of sulindac and atorvastatin in an animal model more relevant to humans, Chang, Clapper and their colleagues used a unique mouse that had genetic alterations that cause them to develop multiple colorectal adenomas, without exposure to carcinogens. "No one had previously tested the effectiveness of this drug combination against colorectal cancer originating from alterations in the genome," Clapper says. "In some ways, using this type of preclinical tumor model represents a new paradigm for doing prevention studies and therapeutic studies."

In the new study, the researchers treated the mice with either drug alone or in combination for 100 days and used colonoscopic examinations to evaluate the presence and size of tumors before and after treatment. In mice that had tumors prior to treatment, only combination therapy reduced the number of adenomas in the colon by the end of the treatment period.

The results were strikingly different in mice that were tumor-free when treatment began. In these mice, exposure to atorvastatin alone or in combination with sulindac resulted in about a three-fold increase in the percentage of mice that were tumor-free by the end of the treatment period. Among these mice, 44 percent of those treated with atorvastatin alone and 30 percent of those treated with both drugs did not develop tumors, compared with 13 percent of mice that received no treatment and nine percent that received sulindac alone. Moreover, atorvastatin treatment completely inhibited the formation of microscopic adenomas in these mice.

The findings demonstrate that the effectiveness of the two drugs at preventing and treating colorectal adenomas depends on whether tumors are present prior to the onset of treatment. "Based on this study, we're able to say that if you don't have a tumor to begin with, maybe Lipitor is best, but if you do have a tumor to begin with, you need the combination therapy," Chang says. "We can start to tailor clinical care based upon the disease state as well as the establishment of tumors."

Moving forward, the researchers plan to study the specific genetic alterations in this particular mouse model, with the goal of identifying molecular pathways that could be targeted with therapies.


'/>"/>

Contact: Diana Quattrone
diana.quattrone@fccc.edu
215-728-7784
Fox Chase Cancer Center
Source:Eurekalert

Related medicine news :

1. Despite Olympic fever, British women remain indifferent about sport
2. More Danish women are physically active than their European neighbors, but remain indifferent to sport
3. German women are more physically active than their European counterparts yet remain indifferent to sport
4. Moffitt researchers say silencing of retinoblastoma gene regulates differentiation of myeloid cells
5. Sleep Specialist Dr. Gerald Suh Differentiates Behavioral from Physiological Sleep Disorders
6. Protein paves the way for correct stem cell differentiation
7. Obese Women With Diabetes May Need Different Workouts Than Men
8. People with low risk for cocaine dependence have differently shaped brain to those with addiction
9. Dr. Kent Stobaugh Retiring from Oral & Maxillofacial Surgeons to Pursue Different Opportunities: SA4i Emphasizes Significant Contributions to People’s Lives
10. Psychological common ground could ease tensions among those with different religious beliefs
11. Pain Intensity May Help Differentiate 2 Skin Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... 22, 2017 , ... In recognition of Colon Cancer Awareness ... on cancer patients, cancer centers and advocacy groups, and MJH Studios™, a leading ... “No Ifs, Ands, or Butts,” that focuses on Colorectal Cancer detection, prevention and ...
(Date:3/22/2017)... ... March 22, 2017 , ... Drs. Jennifer Houck, Lauren Smith, Heather Johnson and ... patients in need of skilled pediatric dentistry in Rock Hill, SC, without ... patients routine treatments, including cavities, sealants and fluoride applications, in a comfortable and fun ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... throughout north Jersey and the New York metropolitan region, is embarking on a ... for homeless families. , At present, more than two and a half million ...
(Date:3/22/2017)... ... March 22, 2017 , ... Schneider Insurance and Financial, a southern Montana ... the Yellowstone Valley region, is launching a charity event aimed at raising local support ... all of Montana State, and is home to a broad variety of animals from ...
(Date:3/22/2017)... ... ... The Senior Citizens League (TSCL) is calling on Congressional leadership to lift ... including the debt held by the Social Security Trust Fund. “Congressional inaction on ... House and Senate budget leaders. “In prior debates to lift the debt ceiling, ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, ... Canada , today announced two new real-world data analyses ... 65 th Annual Pacific Coast Reproductive Society (PCRS) Meeting ... 24 th .   The results being presented are ... 2009 to December 2015 containing data from 15 fertility clinics ...
(Date:3/22/2017)... 22, 2017 NetworkNewsWire Editorial Coverage  ... Deciphering marijuana ... statements by White House officials. Federal laws are at odds ... medical and/or recreational use, and businesses like SinglePoint, Inc. (OTC: ... CRBP), Medical Marijuana, Inc. (OTC: MJNA), Cannabis Science, Inc. (OTC: ...
(Date:3/22/2017)... 2017 Biosensors International Group, Ltd. ("Biosensors" or the ... the enrollment of the first American patient in LEADERS FREE II, its ... will include sites in the United States , ... Italy , and the United Kingdom . ... The BioFreedom drug-coated stent (DCS) ...
Breaking Medicine Technology: